Why Summit Therapeutics Shares Dropped: Two Analyst Moves Shake Confidence
Summit Therapeutics PLC shares slid sharply after two analyst actions in the same session shifted sentiment against the stock. One firm initiated coverage with an Underperform rating and a $7.70 price target, urging exit or short positions, while another reduced its rating from Buy to Neutral and removed its price target, citing competitive data fr…